Stock Research: Medical Developments International

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Medical Developments International

ASX:MVP AU000000MVP2
17
  • Value
    49
  • Growth
    68
  • Safety
    Safety
    30
  • Combined
    52
  • Sentiment
    10
  • 360° View
    360° View
    17
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Medical Developments International Limited delivers emergency medical solutions. It operates in Pain Management (Penthrox inhaled analgesic) and Respiratory (asthma/COPD products). The company serves Australia, the United States, Europe, and Asia. In the last fiscal year, the company had a market cap of $43 million, profits of $16 million, and revenue of $22 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 17 (better than 17% compared with alternatives), overall professional sentiment and financial characteristics for the stock Medical Developments International are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Medical Developments International. The consolidated Growth Rank has a good rank of 68, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 68% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 30 means that the share price of Medical Developments International is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 70% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 49, which means that the company has a riskier financing structure than 51% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 10, indicating professional investors are more pessimistic about the stock than for 90% of alternative investment opportunities. ...read more

more
Index
ASX 300
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
30 36 42 17
Growth
68 43 25 39
Safety
Safety
49 21 47 45
Sentiment
10 34 30 50
360° View
360° View
17 13 14 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
61 62 62 87
Opinions Change
50 50 50 50
Pro Holdings
n/a 14 4 8
Market Pulse
12 59 48 51
Sentiment
10 34 30 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
30 36 42 17
Growth
68 43 25 39
Safety Safety
49 21 47 45
Combined
52 10 23 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
14 75 75 36
Price vs. Earnings (P/E)
57 44 66 13
Price vs. Book (P/B)
100 81 73 23
Dividend Yield
1 1 1 1
Value
30 36 42 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
26 48 95 85
Profit Growth
100 100 23 1
Capital Growth
1 1 29 78
Stock Returns
96 30 3 19
Growth
68 43 25 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
75 70 73 68
Refinancing
68 36 77 37
Liquidity
1 1 1 43
Safety Safety
49 21 47 45

Similar Stocks

Discover high‑ranked alternatives to Medical Developments International and broaden your portfolio horizons.

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Shionogi

TSE:4507
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Towa Pharmaceutical

TSE:4553
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.